Literature DB >> 20555088

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

N Colombo1, M Peiretti, G Parma, M Lapresa, R Mancari, S Carinelli, C Sessa, M Castiglione.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555088     DOI： 10.1093/annonc/mdq244

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  61 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.

Authors:  Nicoletta Staropoli; Domenico Ciliberto; Cirino Botta; Lucia Fiorillo; Anna Grimaldi; Stefania Lama; Michele Caraglia; Angela Salvino; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

3.  Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.

Authors:  Merrina Anugraham; Francis Jacob; Sheri Nixdorf; Arun Vijay Everest-Dass; Viola Heinzelmann-Schwarz; Nicolle H Packer
Journal:  Mol Cell Proteomics       Date:  2014-05-22       Impact factor: 5.911

Review 4.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 5.  Clinical oncologic applications of PET/MRI: a new horizon.

Authors:  Sasan Partovi; Andres Kohan; Christian Rubbert; Jose Luis Vercher-Conejero; Chiara Gaeta; Roger Yuh; Lisa Zipp; Karin A Herrmann; Mark R Robbin; Zhenghong Lee; Raymond F Muzic; Peter Faulhaber; Pablo R Ros
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 6.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

7.  MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line.

Authors:  Yankun Liu; Sugui Han; Yuhui Li; Yan Liu; Di Zhang; Yufeng Li; Jinghua Zhang
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

8.  Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.

Authors:  Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner
Journal:  Mol Cancer Res       Date:  2019-01-03       Impact factor: 5.852

9.  NFAT Overexpression Correlates with CA72-4 and Poor Prognosis of Ovarian Clear-Cell Carcinoma Subtype.

Authors:  Bing Xin; Kai-Qiang Ji; Yi-Si Liu; Xiao-Dong Zhao
Journal:  Reprod Sci       Date:  2020-10-30       Impact factor: 3.060

10.  CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.

Authors:  Hiroaki Yasui; Hiroaki Kajiyama; Satoshi Tamauchi; Shiro Suzuki; Yang Peng; Nobuhisa Yoshikawa; Mai Sugiyama; Kae Nakamura; Fumitaka Kikkawa
Journal:  Clin Exp Metastasis       Date:  2019-09-21       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.